{"id":"d80b9210-9fad-5a60-843f-f501dbd39468","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-rat-bioavailability","predicate":"reported_relationship","statement":"Rat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"0cb3bf71-bbb3-5b34-af64-c539ff9db24c","mechanism_event_label":"Rat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"cd5dfd74-768b-5418-a507-0cd91a9fc0f8","slug":"rat-ra-absolute-oral-bioavailability","display_name":"Rat absolute oral bioavailability of RA","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"0cb3bf71-bbb3-5b34-af64-c539ff9db24c","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-rat-bioavailability-event","event_type":"experimental_observation","label":"Rat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.","description":"### ra-rat-bioavailability\n\nRat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.\nTable 2; dose-normalized oral versus IV AUC. These values are not established human bioavailability.\nModel and exposure: Male rats, six per group; 0.625 mg/kg IV reference; LC-MS/MS.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality | 2017 | https://pubs.rsc.org/en/content/articlehtml/2017/ra/c6ra28237g | Access: Publisher-indexed primary Methods, Results and Table 2 read through web retrieval; local HTML download blocked.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"cd5dfd74-768b-5418-a507-0cd91a9fc0f8","slug":"rat-ra-absolute-oral-bioavailability","display_name":"Rat absolute oral bioavailability of RA","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Publisher-indexed primary Methods, Results and Table 2 read through web retrieval; local HTML download blocked.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Male rats, six per group; 0.625 mg/kg IV reference; LC-MS/MS.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Rat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality | https://pubs.rsc.org/en/content/articlehtml/2017/ra/c6ra28237g","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-rat-bioavailability; Table 2; dose-normalized oral versus IV AUC. These values are not established human bioavailability.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"595bc369-10dc-5760-9b27-fc61b7068380","evidence_kind":"source_excerpt","locator":"Lines 27-33","start_line":27,"end_line":33,"excerpt":"### ra-rat-bioavailability\n\nRat absolute oral bioavailability was 1.69%, 1.28% and 0.91% at 12.5, 25 and 50 mg/kg oral RA, respectively.\nTable 2; dose-normalized oral versus IV AUC. These values are not established human bioavailability.\nModel and exposure: Male rats, six per group; 0.625 mg/kg IV reference; LC-MS/MS.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality | 2017 | https://pubs.rsc.org/en/content/articlehtml/2017/ra/c6ra28237g | Access: Publisher-indexed primary Methods, Results and Table 2 read through web retrieval; local HTML download blocked.","model_system":"Male rats, six per group; 0.625 mg/kg IV reference; LC-MS/MS.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}